WRF
ALXN

Waddell & Reed Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

Waddell & Reed Financial’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,000
Closed -$612K – 595
2016
Q4 		$612K Buy
+5,000
New +$612K ﹤0.01% 563

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Waddell & Reed Financial's ALXN Position: Q2 2019 in Review

Waddell & Reed Financial sold out of Alexion Pharmaceuticals (ALXN) in Q2 2019, closing a stake of 20,100 shares — an estimated $2.72M sold.

Waddell & Reed Financial first reported a position in ALXN in Q2 2013 and held it in 24 quarters. The position peaked at $609M in Q4 2015. 636 funds tracked by Wall St. Rank hold ALXN as of Q2 2019.

  • Waddell & Reed Financial reported no remaining Alexion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Waddell & Reed Financial sold 20,100 Alexion Pharmaceuticals shares in Q2 2019, an estimated $2.72M.
  • Waddell & Reed Financial first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 24 quarters.
  • Waddell & Reed Financial's Alexion Pharmaceuticals position peaked at $609M in Q4 2015.
  • 636 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2019.

Based on Waddell & Reed Financial's 13F filing for Q2 2019, filed 14 Aug 2019.